PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells

  • Authors:
    • Yufeng Wang
    • Yasuhiro Kuramitsu
    • Byron Baron
    • Takao Kitagawa
    • Kazuhiro Tokuda
    • Junko Akada
    • Shin-Ichiro Maehara
    • Yoshihiko Maehara
    • Kazuyuki Nakamura
  • View Affiliations

  • Published online on: December 14, 2016     https://doi.org/10.3892/ijo.2016.3804
  • Pages: 606-612
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

LY294002 and wortmannin are chemical compounds that act as potent inhibitors of phosphoinositide 3-kinases (PI3Ks). Both of them are generally used to inhibit cell proliferation as cancer treatment by inhibiting the PI3K/protein kinase B (AKT) signaling pathway. In this study, LY294002 (but not wortmannin) showed an abnormal ability to enhance AKT phosphorylation (at Ser472) specifically in gemcitabine (GEM)-resistant pancreatic cancer (PC) cell lines PK59 and KLM1-R. LY294002 was shown to activate AKT and accumulate phospho-AKT at the intracellular membrane in PK59, which was abolished by treatment with AKTi-1/2 or wortmannin. Inhibiting AKT phosphorylation by treatment with AKTi-1/2 or wortmannin further enhanced LY294002-induced cell death in PK59 and KLM1-R cells. In addition, treatment with wortmannin alone failed to inhibit cell proliferation in both PK59 and KLM1-R cells. Thus, our results reveal that LY294002 displays the opposite effect on PI3K-dependent AKT phosphorylation, which maintains cell survival from the cytotoxicity introduced by LY294002 itself in GEM-resistant pancreatic cancer cells. We suggest that targeting the PI3K/AKT signaling pathway with inhibitors may be counterproductive for patients with PC who have acquired GEM-resistance.
View Figures
View References

Related Articles

Journal Cover

February-2017
Volume 50 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang Y, Kuramitsu Y, Baron B, Kitagawa T, Tokuda K, Akada J, Maehara S, Maehara Y and Nakamura K: PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Int J Oncol 50: 606-612, 2017
APA
Wang, Y., Kuramitsu, Y., Baron, B., Kitagawa, T., Tokuda, K., Akada, J. ... Nakamura, K. (2017). PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. International Journal of Oncology, 50, 606-612. https://doi.org/10.3892/ijo.2016.3804
MLA
Wang, Y., Kuramitsu, Y., Baron, B., Kitagawa, T., Tokuda, K., Akada, J., Maehara, S., Maehara, Y., Nakamura, K."PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells". International Journal of Oncology 50.2 (2017): 606-612.
Chicago
Wang, Y., Kuramitsu, Y., Baron, B., Kitagawa, T., Tokuda, K., Akada, J., Maehara, S., Maehara, Y., Nakamura, K."PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells". International Journal of Oncology 50, no. 2 (2017): 606-612. https://doi.org/10.3892/ijo.2016.3804